C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.38 AUD 0.73% Market Closed
Market Cap: 153.4m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Accounts Receivables
AU$4.8m
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
4%
R
Respiri Ltd
ASX:RSH
Accounts Receivables
AU$253.1k
CAGR 3-Years
23%
CAGR 5-Years
9%
CAGR 10-Years
12%
ImpediMed Ltd
ASX:IPD
Accounts Receivables
AU$2.2m
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
17%
Cochlear Ltd
ASX:COH
Accounts Receivables
AU$490.7m
CAGR 3-Years
18%
CAGR 5-Years
9%
CAGR 10-Years
9%
Optiscan Imaging Ltd
ASX:OIL
Accounts Receivables
AU$1.6m
CAGR 3-Years
8%
CAGR 5-Years
30%
CAGR 10-Years
9%
EMvision Medical Devices Ltd
ASX:EMV
Accounts Receivables
AU$16.2k
CAGR 3-Years
N/A
CAGR 5-Years
-20%
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
153.4m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.01 AUD
Undervaluation 31%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Accounts Receivables?
Accounts Receivables
4.8m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Accounts Receivables amounts to 4.8m AUD.

What is Cyclopharm Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
4%

Over the last year, the Accounts Receivables growth was -51%. The average annual Accounts Receivables growth rates for Cyclopharm Ltd have been -1% over the past three years , 8% over the past five years , and 4% over the past ten years .

Back to Top